Table 4.
The association between pre-treatment biomarkers of systemic inflammation and risk of immune-related adverse event in all patients, and 12-week landmark and 24-week landmark cohorts. Bold/italics represent statistically significant findings (p < 0.005).
| Characteristics | All | 12-Week Landmark | 24-Week Landmark | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Without irAE | With irAE | OR (95% CI) p |
Without irAE | With irAE | OR (95% CI) p |
Without irAE | With irAE | OR (95% CI) p |
||
| n = 179 | n = 83 | n = 130 | n = 76 | n = 105 | n = 75 | |||||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |||||
| White Cell Count | ≤11.0 × 109/L | 109 (61) | 64 (77) |
2.16
(1.20–3.91) 0.011 |
89 (68) | 59 (78) |
1.60
(0.83–3.08) 0.158 |
80 (76) | 59 (79) |
1.15
(0.57–2.35) 0.696 |
| >11.0 × 109/L | 70 (39) | 19 (23) | 41 (32) | 17 (22) | 25 (24) | 16 (21) | ||||
| Median (IQR) | 10.1 (7.8–13.2) |
8.5 (6.8–10.8) |
0.008 | 9.5 (7.3–11.6) |
8.4
(6.8–10.6) |
0.191 |
9.3
(7.1–11.5) |
8.4
(6.8–10.6) |
0.198 | |
| Neutrophil Count | ≤7.5 × 109/L | 101 (56) | 63 (76) |
2.43
(1.35–4.36) 0.003 |
84 (65) | 58 (76) |
1.76
(0.93–3.34) 0.082 |
70 (67) | 58 (77) |
1.71
(0.87–3.35) 0.120 |
| >7.5 × 109/L | 78 (44) | 20 (24) | 46 (35) | 18 (24) | 35 (33) | 17 (23) | ||||
| Median (IQR) | 6.8 (5.1–10.0) |
5.9 (4.5–7.4) |
0.010 |
5.8
(4.5–7.4) |
6.1 (4.8–8.4) | 0.245 |
5.7
(4.6–7.9) |
6.0
(4.6–8.3) |
0.624 | |
| NLR | <5 | 104 (58) | 51 (61) |
1.15
(0.67–1.96) 0.608 |
89 (68) | 49 (64) |
0.84
(0.46–1.52) 0.557 |
75 (71) | 49 (65) |
0.76
(0.40–1.43) 0.384 |
| ≥5 | 75 (42) | 32 (39) | 41 (32) | 27 (36) | 30 (29) | 26 (35) | ||||
| Median (IQR) | 4.3 (2.8–7.4) |
4.3 (2.8–6.5) |
0.122 | 3.8 (2.6–2.0) | 3.9 (2.8–5.7) | 0.524 |
3.6
(2.6–5.1) |
4.4
(2.9–6.6) |
0.737 | |
| PLR | ≤180 | 51 (28) | 28 (34) |
1.28
(0.73–2.23) 0.390 |
41 (32) | 28 (37) |
1.27
(0.70–2.30) 0.437 |
39 (37) | 28 (62) |
1.01
(0.55–1.86) 0.979 |
| >180 | 128 (72) | 55 (66) | 89 (68) | 48 (66) | 66 (63) | 47 (38) | ||||
| Median (IQR) | 225 (169–321) |
238 (155–238) |
0.548 |
219
(165–306) |
226
(145–336) |
0.477 |
202
(150–276) |
260
(163–352) |
0.216 | |
| Albumin | ≥35 g/L | 86 (48) | 55 (66) |
2.12
(1.24–3.65) 0.006 |
71 (55) | 53 (70) |
1.91
(1.05–3.49) 0.034 |
62 (59) | 52 (69) |
1.57
(0.84–2.93) 0.159 |
| <35 g/L | 93 (52) | 28 (34) | 59 (45) | 23 (30) | 43 (41) | 23 (31) | ||||
| Median (IQR) | 34 (29–38) | 36 (32–41) | 0.005 | 35 (31–39) | 37 (33–41) | 0.07 | 35 (31–38) | 36 (33–41) | 0.285 | |
| PNI | ≥45 | 66 (37) | 39 (47) |
1.52
(0.90–2.57) 0.121 |
55 (42) | 38 (50) |
1.36
(0.77–2.41) 0.285 |
49 (47) | 37 (49) |
1.11
(0.61–2.01) 0.724 |
| <45 | 113 (63) | 44 (53) | 75 (68) | 38 (50) | 56 (53) | 38 (51) | ||||
| Median (IQR) | 42.0 (36.5–47.5) |
44.8 (40.3–49.0) |
0.411 | 43.0 (38.7–48.0) | 45.0 (41.4–49.5) | 0.679 |
43.2
(37.9–46.3) |
45.6
(40.8–49.3) |
0.743 | |
| SIPS | 0 | 65 (36) | 44 (53) |
1.98
(1.67–3.35) 0.011 |
56 (43) | 42 (55) |
1.63
(0.92–2.88) 0.09 |
48 (46) | 42 (56) |
1.51
(0.84–2.74) 0.174 |
| 1/2 | 114 (64) | 39 (47) | 74 (57) | 34 (45) | 57 (54) | 33 (44) | ||||